Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Li-Xuan Qin

Showing results (81-90 of 131) with videos related to

Pageof 14
Sort By:
Oncogene|May 24, 2018
PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescenceMary E Klein, Mark A Dickson, Cristina Antonescu, et al.
Annals of Surgery|October 23, 2025
Accuracy of Flexible Sigmoidoscopy and MRI in Restaging Rectal Cancer after Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical TrialHannah Williams, Dana M Omer, Floris S Verheij, et al.
Genes, Chromosomes & Cancer|July 15, 2015
Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysisAimee M Crago, Juliann Chmielecki, Mara Rosenberg, et al.
International Journal of Radiation Oncology, Biology, Physics|August 6, 2023
Compliance and Toxicity of Total Neoadjuvant Therapy for Rectal Cancer: A Secondary Analysis of the OPRA TrialFloris S Verheij, Dana M Omer, Sabrina T Lin, et al.
Cancer Research|March 13, 2020
Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for SurvivalGeorge Z Li, Tomoyo Okada, Young-Mi Kim, et al.
JAMA Oncology|April 29, 2016
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical TrialMark A Dickson, Gary K Schwartz, Mary Louise Keohan, et al.
Neoplasia (New York, N.Y.)|March 10, 2015
Molecular subtypes of uterine leiomyosarcoma and correlation with clinical outcomeJoyce N Barlin, Qin C Zhou, Mario M Leitao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcomaMark A Dickson, William D Tap, Mary Louise Keohan, et al.
The Oncologist|June 20, 2019
A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal TumorEvan Rosenbaum, Ciara Kelly, Sandra P D'Angelo, et al.
Molecular Oncology|January 21, 2015
Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasionVictor P Andrade, Mary Morrogh, Li-Xuan Qin, et al.
Pageof 14

Showing results (81-90 of 131) with videos related to

Sort By:
Pageof 14
Oncogene|May 24, 2018
PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescenceMary E Klein, Mark A Dickson, Cristina Antonescu, et al.
Annals of Surgery|October 23, 2025
Accuracy of Flexible Sigmoidoscopy and MRI in Restaging Rectal Cancer after Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical TrialHannah Williams, Dana M Omer, Floris S Verheij, et al.
Genes, Chromosomes & Cancer|July 15, 2015
Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysisAimee M Crago, Juliann Chmielecki, Mara Rosenberg, et al.
International Journal of Radiation Oncology, Biology, Physics|August 6, 2023
Compliance and Toxicity of Total Neoadjuvant Therapy for Rectal Cancer: A Secondary Analysis of the OPRA TrialFloris S Verheij, Dana M Omer, Sabrina T Lin, et al.
Cancer Research|March 13, 2020
Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for SurvivalGeorge Z Li, Tomoyo Okada, Young-Mi Kim, et al.
JAMA Oncology|April 29, 2016
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical TrialMark A Dickson, Gary K Schwartz, Mary Louise Keohan, et al.
Neoplasia (New York, N.Y.)|March 10, 2015
Molecular subtypes of uterine leiomyosarcoma and correlation with clinical outcomeJoyce N Barlin, Qin C Zhou, Mario M Leitao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcomaMark A Dickson, William D Tap, Mary Louise Keohan, et al.
The Oncologist|June 20, 2019
A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal TumorEvan Rosenbaum, Ciara Kelly, Sandra P D'Angelo, et al.
Molecular Oncology|January 21, 2015
Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasionVictor P Andrade, Mary Morrogh, Li-Xuan Qin, et al.
Pageof 14